Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company based in New York City and Waltham, MA. They are dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases. With their lead antibody, DNTH103, they aim to improve the lives of patients by offering less frequent and more convenient self-administered subcutaneous injections through purposeful engineering with extended half-life, improved potency, and high selectivity for the active C1s complement protein that drives disease pathology.
Supported by a strong syndicate of experienced life science investors, including 5AM Ventures, Avidity Partners, Fairmount, Fidelity Management Research Company, Tellus BioVentures, Venrock, Wedbush Healthcare Partners, and others, Dianthus Therapeutics is led by a multidisciplinary team of biotech entrepreneurs and scientists. Their team is committed to delivering novel and highly differentiated monoclonal antibodies that target validated and emerging complement targets with improved selectivity and potency over existing therapies. Dianthus Therapeutics is currently seeking visionary, entrepreneurial, and passionate individuals to join their team and make a lasting impact in the lives of patients through novel complement therapeutics.
Generated from the website